ABT vs AZN
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. AZN: AstraZeneca is a global biopharmaceutical leader driving innovation in oncology, rare diseases, and specialized biopharmaceuticals to transform patient outcomes.
Side-by-side fundamentals
| Metric | ABT | AZN | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $105.70 | $169.64 | |
| Market cap as of 2026-08-03 | $184.1B | $197.3B | |
| P/E as of 2026-08-03 | 34.02 | 25.47 | AZN lower |
| PEG as of 2026-08-03 | 3.63 | 2.64 | AZN lower |
| Net margin as of 2026-08-03 | +11.7% | +17.0% | AZN higher |
| Gross margin as of 2026-08-03 | +56.8% | +81.3% | AZN higher |
| Operating margin as of 2026-08-03 | +15.8% | +22.8% | AZN higher |
| ROE as of 2026-08-03 | +12.2% | +21.7% | AZN higher |
| ROA as of 2026-08-03 | +6.9% | +9.1% | AZN higher |
| Debt / equity as of 2026-08-03 | 0.65 | 0.64 | AZN lower |
| Revenue growth (YoY) as of 2026-08-03 | +8.1% | +8.6% | AZN higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +9.8% | AZN higher |
| Dividend yield as of 2026-08-03 | +2.4% | +1.9% | ABT higher |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-08-03 | 0.16 | 1.34 | |
| 1-year return as of 2026-07-31 close | -16.2% | +16.7% | AZN higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.